Back to top
more

Synlogic (SYBX)

(Delayed Data from NSDQ)

$1.88 USD

1.88
20,014

+0.01 (0.27%)

Updated Apr 22, 2024 10:41 AM ET

After-Market: $1.84 -0.04 (-1.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Synlogic, Inc. (SYBX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

by Zacks Equity Research

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

Do Options Traders Know Something About Synlogic (SYBX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.

Synlogic (SYBX) Catches Eye: Stock Jumps 12.9%

by Zacks Equity Research

Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

Biomarin to File Regulatory Applications for Vosoritide in Q3

by Zacks Equity Research

BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.

Will Synlogic Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Synlogic.

BioMarin to Begin Early-Stage Study on Gene Therapy for PKU

by Zacks Equity Research

BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

Can The Uptrend Continue for Synlogic?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Synlogic

Will Synlogic Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Synlogic.

Synlogic Discontinues Development of SYNB1020, Stock Down

by Zacks Equity Research

Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

    Synlogic Enters Oversold Territory

    by Zacks Equity Research

    Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

    Synlogic (SYBX) Enters Cancer Collaboration with Roche

    by Zacks Equity Research

    Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

    Will Synlogic, Inc (SYBX) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    Synlogic, Inc (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Why Synlogic (SYBX) Could Be a Potential Winner

    by Zacks Equity Research

    Synlogic (SYBX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

      Synlogic (SYBX) Enters Oversold Territory

      by Zacks Equity Research

      Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

        Why Synlogic (SYBX) Might Surprise This Earnings Season

        by Zacks Equity Research

        Synlogic (SYBX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

          Zacks.com highlights: Enterprise Financial Services, LCI Industries, Simpson Manufacturing and Synlogic

          by Zacks Equity Research

          Zacks.com highlights: Enterprise Financial Services, LCI Industries, Simpson Manufacturing and Synlogic

            New Analyst Coverage Puts the Spotlight on These 4 Stocks

            by Zacks Equity Research

            More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.